At the European Society for Medical Oncology (ESMO) Congress this week, investigators presented data for a new and potentially important drug, ribociclib (Novartis). This oral medication is ...

The team found adding ribociclib, a drug that belongs to a class of CDK4/6 inhibitors, to standard hormone therapy not only ...

Get detailed information on Ribociclib, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Baylor Medicine’s Interstitial Lung Disease (ILD) program offers specialized and multidisciplinary care. We bring together a unique team of physicians of multiple sub-specialties for patients with a ...

The ribociclib population is more broad ... Another benefit of this medication is we are not too worried about the grade 5 ILD [interstitial lung disease] with Dato-DXd compared with T-DXd.

Ribociclib in combination with an aromatose inhibitor for previously untreated advanced or metastatic hormone receptor-positive, her2-negative breast cancer. The NICE appraisal committee wanted to ...

Diffuse (interstitial) lung disease includes a wide variety of relatively uncommon conditions presenting with characteristic clusters of clinical features and marked by an immune response. There ...

Interstitial lung disease (ILD) is a broad term for a group of conditions that cause lung inflammation and/or fibrosis ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

She discusses major event objectives and agenda items related to ILD and idiopathic pulmonary fibrosis (IPF), including recommended diagnostic and management strategies. Padilla also emphasizes ...

Their research suggested that neoadjuvant therapy with a combination of ribociclib and letrozole could be an alternative to multi-drug neoadjuvant chemotherapy. The trial involved high risk ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients ...